JP2008506709A5 - - Google Patents

Download PDF

Info

Publication number
JP2008506709A5
JP2008506709A5 JP2007521684A JP2007521684A JP2008506709A5 JP 2008506709 A5 JP2008506709 A5 JP 2008506709A5 JP 2007521684 A JP2007521684 A JP 2007521684A JP 2007521684 A JP2007521684 A JP 2007521684A JP 2008506709 A5 JP2008506709 A5 JP 2008506709A5
Authority
JP
Japan
Prior art keywords
group
peptidomimetic
seq
compound
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007521684A
Other languages
English (en)
Japanese (ja)
Other versions
JP5048486B2 (ja
JP2008506709A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/025182 external-priority patent/WO2006020040A2/en
Publication of JP2008506709A publication Critical patent/JP2008506709A/ja
Publication of JP2008506709A5 publication Critical patent/JP2008506709A5/ja
Application granted granted Critical
Publication of JP5048486B2 publication Critical patent/JP5048486B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007521684A 2004-07-16 2005-07-15 アポリポタンパク質a1の模倣物とその使用 Expired - Fee Related JP5048486B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58872204P 2004-07-16 2004-07-16
US60/588722 2004-07-16
PCT/US2005/025182 WO2006020040A2 (en) 2004-07-16 2005-07-15 Apolipoprotein a1 mimetics and uses thereof

Publications (3)

Publication Number Publication Date
JP2008506709A JP2008506709A (ja) 2008-03-06
JP2008506709A5 true JP2008506709A5 (enExample) 2008-09-04
JP5048486B2 JP5048486B2 (ja) 2012-10-17

Family

ID=35907926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007521684A Expired - Fee Related JP5048486B2 (ja) 2004-07-16 2005-07-15 アポリポタンパク質a1の模倣物とその使用

Country Status (12)

Country Link
US (3) US7569546B2 (enExample)
EP (1) EP1771473B1 (enExample)
JP (1) JP5048486B2 (enExample)
KR (1) KR101185609B1 (enExample)
CN (1) CN101076541A (enExample)
AU (1) AU2005275009B2 (enExample)
BR (1) BRPI0513402A (enExample)
CA (1) CA2574007A1 (enExample)
IL (1) IL180733A (enExample)
NO (1) NO20070876L (enExample)
TW (1) TWI377066B (enExample)
WO (1) WO2006020040A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
BRPI0513402A (pt) * 2004-07-16 2008-05-06 Tufts College miméticos de apolipoproteìna a1 e usos dos mesmos
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
RU2414236C2 (ru) 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EA200900786A1 (ru) * 2005-04-29 2009-10-30 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Пептид в качестве лекарственного средства и способ лечения патологий, связанных с воспалительными процессами, посредством пептида
US8163699B2 (en) * 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
EP2049137A4 (en) * 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
CA2672131C (en) * 2006-12-13 2016-06-07 The Regents Of The University Of California Potent and selective mediators of cholesterol efflux
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US20110178029A1 (en) * 2007-09-14 2011-07-21 Ambrx, Inc. Modified Human Apolipoprotein A-1 and Their Uses
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US20110020242A1 (en) * 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
DK2396017T3 (en) 2009-02-16 2015-09-14 Cerenis Therapeutics Holding Sa Apolipoprotein A-I-mimetika
EP2582379A4 (en) * 2010-06-15 2013-12-04 Matthew C Lawyer COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS
HUE042314T2 (hu) * 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
CN105050614B (zh) 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
CN103910802B (zh) * 2014-04-24 2017-01-11 华中科技大学 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
FR3026409B1 (fr) * 2014-09-26 2018-03-30 Centre National De La Recherche Scientifique (Cnrs) Procede de criblage de molecules interferentes
EP3273944B1 (en) * 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS
TW202130652A (zh) 2017-01-19 2021-08-16 美國衛生與公眾服務部 Apoc-ii擬肽
EP4135747A1 (en) 2020-04-16 2023-02-22 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein- based complexes
JP2023543498A (ja) 2020-10-01 2023-10-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
JP2024514154A (ja) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
EP4504233A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
EP4504150A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating eye diseases using lipid binding protein-based complexes
CN120344255A (zh) 2022-06-10 2025-07-18 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法
EP4536269A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein-based complexes
AU2024207875A1 (en) 2023-01-13 2025-07-24 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7105635B2 (en) * 2002-06-04 2006-09-12 The University Of Toledo Cyclic beta-sheet peptides useful as apoptotic/cytotoxic cancer agents
BRPI0513402A (pt) * 2004-07-16 2008-05-06 Tufts College miméticos de apolipoproteìna a1 e usos dos mesmos
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
RU2414236C2 (ru) * 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол

Similar Documents

Publication Publication Date Title
JP2008506709A5 (enExample)
JP5683951B2 (ja) 長期間作用性ペプチド類似体のための組成物
JP2006508179A5 (enExample)
AU2007284801A1 (en) Salicylanilides enhance oral delivery of therapeutic peptides
WO2012050227A1 (en) Peptide derivative
JP2011518179A5 (enExample)
RU2007110981A (ru) Урокортин iii и его использование
CA2697504A1 (en) Salicylanilide modified peptides for use as oral therapeutics
RU2009110452A (ru) Галеновые составы алискирена
AR025307A1 (es) Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
JP2008522980A5 (enExample)
DK2783697T3 (en) VIP Fragments and uses thereof
JP2009523156A5 (enExample)
JP2007506713A (ja) 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用
JP2010513311A5 (enExample)
ES2349153T3 (es) Inhibidores del virus de la hepatitis c.
JP5421257B2 (ja) プラスミノーゲン活性化因子阻害物質1由来のペプチドおよびその使用
SK150196A3 (en) Peptides with immunomodulatory effects, pharmaceutical formulations containing them and their use
JP2005514385A (ja) プリオン阻害ペプチド及びその誘導体
CN101657465B (zh) 肽、组合物及其应用
CN114364691B (zh) 作为纤维化基质积累的抑制剂的肽
ES2254938T3 (es) Mutantes de quimioquinas que poseen biodisponibilidad oral mejorada.
US6596692B1 (en) Substance P analogs for the treatment of cancer
JP2014198711A (ja) Ct阻害4価ペプチドおよびコレラ治療薬
JP4332618B2 (ja) 抗hiv剤